Therapy of Histiocytosis X With Vincristine, Vinblastine, and Cyclophosphamide

Abstract

We report the use of vincristine sulfate, vinblastine sulfate, and cyclophosphamide in the treatment of children with histiocytosis X. No children with solitary eosinophilic granulomas are included in this study. The complete remission rates for the three drugs were 50%, 20%, and 36%, respectively; and the complete remission plus partial remission rates are 50%, 55%, and 63%, respectively. Because of the small numbers of patients involved, and the design of the study, we could reach no conclusions regarding the relative efficacy of the drugs. We discuss factors influencing the response and present tabulated data regarding age, degree of involvement, duration of therapy, and result of therapy for each patient.